Q1 Results: Brokerages Cut Cipla’s Target On Weak India Performance
Metformin Bilayer, medicinal tablets manufactured by Sun Pharmaceuticals Industries Ltd., are photographed at company’s lab in Mumbai. (Photographer: Abhijit Bhatlekar/Bloomberg News)

Q1 Results: Brokerages Cut Cipla’s Target On Weak India Performance

Most analysts have cut their target price on Cipla Ltd.’s while retaining their rating on the drugmaker.This comes after the drugmaker’s weak domestic sales—after it realigned its distribution for ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.